What is Maravai LifeSciences Holdings, Inc.'s cygnus — R&D?

Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — R&D of $375K in Q2 2026.

How has Maravai LifeSciences Holdings, Inc.'s cygnus — R&D changed year-over-year?

Maravai LifeSciences Holdings, Inc.'s cygnus — R&D decreased by 27.3% year-over-year, from $516K to $375K.

What does cygnus — R&D mean?

Represents expenditures focused on the innovation, development, and improvement of products within the Biologics Safety Testing segment. This investment is critical for maintaining a competitive edge and ensuring the long-term relevance of the segment's product portfolio. High levels of R&D spending indicate a commitment to future growth and technological leadership.

Maravai LifeSciences Holdings, Inc. (MRVI) Cygnus — R&D

Screener

Other segment segments

TriLink

$2.3M—

Similar metrics at other companies

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

INSMOther external R&D expenses — R&D

$48.84M+71.7%

MUAEBU — R&D

$109M+0.9%

MUCDBU — R&D

$358M+76.4%

Other financials

Income statement

See full

Revenue$51.4M+8.5%

Gross profit$20.7M+166%

Operating income-$15.1M+77.2%

Net income-$12.4M+68.6%

EPS (diluted)-$0.08+70.4%

Balance sheet

See full

Cash & equivalents$70.6M-73.8%

Total debt$176.7M-52.4%

Total equity$204.6M-23.0%

Total assets$603.7M-32.7%

Cash flow

See full

Operating cash flow$4.0M+139%

CapEx$370.0K-87.1%

Free cash flow$3.6M+128%

Valuation

See full

Market cap$918.96M+210%

Enterprise value$1.03B+158%

P/S4.4×+3.1×

Profitability

See full

Gross margin34.9%+4.4pp

Operating margin-56.1%-21.3pp

Net margin-37.1%-13.6pp

FCF margin-17.2%—

Returns & leverage

See full

Return on equity-32.9%-9.4pp

Debt / equity0.9×-0.5×

Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:03 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001823239-26-000059

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Gross profit	20,650	7,768	54,351	15,493
Operating expenses:
Selling, general and administrative	32,070	38,715	61,162	78,279
Research and development	3,702	4,882	7,591	9,770
Goodwill impairment	—	30,449	—	42,884
Restructuring	(33)	—	2,845	—
Total operating expenses	35,739	74,046	71,598	130,933
Loss from operations	(15,089)	(66,278)	(17,247)	(115,440)

Item 1. Financial Statements

FAQ

What is Maravai LifeSciences Holdings, Inc.'s cygnus — R&D?: Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — R&D of $375K in Q2 2026.
How has Maravai LifeSciences Holdings, Inc.'s cygnus — R&D changed year-over-year?: Maravai LifeSciences Holdings, Inc.'s cygnus — R&D decreased by 27.3% year-over-year, from $516K to $375K.
What does cygnus — R&D mean?: Represents expenditures focused on the innovation, development, and improvement of products within the Biologics Safety Testing segment. This investment is critical for maintaining a competitive edge and ensuring the long-term relevance of the segment's product portfolio. High levels of R&D spending indicate a commitment to future growth and technological leadership.